Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 199

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 199
---
9.4 million. This decrease is mainly explained by (i) the decrease in the operating expenses.

Cash flows from / (used in) investing activities

The Company's net cash flows from investing activities for the year ended December 31, 2024 amounted to €9.2 million and mainly included a €4.2 million of current financial instrument with a July 2024 fixed term and various non current financial assets sales for a total of €5.0 million to cope with Company dollars cash needs. These cash in were partially offset by acquisitions of property, plant and equipment and intangible assets for a net amount €0.4 million. As a reminder, net cash flow used in investing activities for the year ended December 31, 2023 amounted to €20.6 million and were mainly composed of a disposal of a non-current financial instrument which generated a net cash collection of €22.8 million partially offset by acquisitions of property, plant and equipment and intangible assets for a net amount €2.2 million.

Cash flows from / (used in) financing activities

The Company's net cash flows used in financing activities for the year ended December 31, 2024 increased by €4.0 million to €6.0 million for the year ended December 31, 2024 as compared to net cash flows from financing activities of €2.0 million for the year ended December 31, 2023.

Loan repayments amounted to €8.9 million for the year ended December 31, 2024 as compared to €2.4 million for the year ended December 31, 2023. The start of PGE loans repayment in 2024 result in an increase in repayment amounting to €7.0 million.

Receipts from capital transactions amount to €2.9 million in 2024, compared with €0.4 million in 2023. The change is mainly explained by the amount received from a new equity partner for €2.9 million.

Comparisons for the year ended December 31, 2022 and 2023

The following table sets forth cash flow data for the years ended December 31, 2022 and 2023:

                                                              Year ended December 31,                  
                                                              2022                         2023        
                                                              (in thousands)                           
  Cash flows from / (used in) operating activities            € (19,155)                   € (32,559)  
 ─────────────────────────────────────────────────────────────────────────